Abnormal Fundus Autofluorescence Results of Patients in Long-term Treatment with Deferoxamine

被引:31
作者
Viola, Francesco [1 ]
Barteselli, Giulio [1 ]
Dell'Arti, Laura [1 ]
Vezzola, Diego [1 ]
Villani, Edoardo [1 ]
Mapelli, Chiara [1 ]
Zanaboni, Laura [2 ]
Cappellini, Maria D. [2 ]
Ratiglia, Roberto [1 ]
机构
[1] Univ Milan, UO Oculist, Fdn IRCCS Ca Granda, Osped Maggiore Policlin, I-20122 Milan, Italy
[2] Univ Milan, UO Med Interna, Ctr Anemie Congenite, Fdn IRCCS Ca Granda,Osped Maggiore Policlin, I-20122 Milan, Italy
关键词
RETINAL-PIGMENT EPITHELIUM; OCULAR TOXICITY; MACULAR DEGENERATION; HEMODIALYZED PATIENTS; INDUCED RETINOPATHY; POTENTIAL FACTOR; IRON OVERLOAD; ALBINO-RAT; DESFERRIOXAMINE; THERAPY;
D O I
10.1016/j.ophtha.2012.01.039
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To describe and classify patterns of abnormal fundus autofluorescence (FAF) of patients with beta-thalassemia receiving long-term treatment with deferoxamine (DFO). Design: Prospective, cross-sectional, case-control study. Participants: A total of 197 consecutive patients with beta-thalassemia major or intermedia with at least 10 years of treatment with DFO were recruited in a tertiary referral center in Milan, Italy, and were investigated. Seventy-nine thalassemic patients without a history of chelation therapy were included as a control group. Methods: All of the patients were investigated using best-corrected visual acuity (BCVA), fundus photography, and FAF imaging by confocal scanning laser ophthalmoscopy (cSLO) and were compared with the control group. Main Outcome Measures: Identification of abnormal FAF patterns in thalassemic patients treated with long-term DFO and their progression and relationship with visual function. Results: Abnormal FAF not related to other diseases was observed in 18 of the 197 patients (9%) and was classified into 4 phenotypic patterns: minimal change, focal, patchy, and speckled. The abnormal increased or decreased FAF was bilateral in all the cases, and only in some cases did it correspond to funduscopically visible alterations. There were no FAF abnormalities in the control group. During the follow-up, progressive FAF changes related to retinal pigment epithelium (RPE) damage occurred in the patchy pattern, associated with decreasing BCVA. Patients with speckled and focal patterns showed limited or no changes in FAF during the follow-up. No changes in FAF were found in patients with a minimal change pattern. No treated patient with a normal baseline examination demonstrated FAF changes. Patients with patterns other than the minimal change showed significant BCVA deterioration (P < 0.001). Conclusions: Various phenotypic patterns of abnormal FAF can be identified with cSLO imaging. Fundus autofluorescence is a helpful, fast, and noninvasive tool for monitoring the status of the macula in patients at risk of DFO toxicity. It may be useful in the decision to discontinue or switch the therapy in cases of particular high risk for disease progression. The progressive alteration of the RPE suggests an important role of pathologic RPE changes in the evolution of visual loss during long-term treatment with DFO. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1693-1700 (c) 2012 by the American Academy of Ophthalmology.
引用
收藏
页码:1693 / 1700
页数:8
相关论文
共 30 条
[1]   Deferoxamine-related ocular toxicity - Incidence and outcome in a pediatric population [J].
Baath, Jasrajbir S. ;
Lam, Wai-Ching ;
Kirby, Melanie ;
Chun, Anne .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (06) :894-899
[2]   Bull's eye maculopathy with deferoxamine [J].
Bansal, V ;
Elgarbly, I ;
Ghanchi, FD ;
Atkinson, PL .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (06) :420-421
[3]  
BENE C, 1989, CLIN NEPHROL, V31, P45
[4]   Classification of fundus autofluorescence patterns in early age-related macular disease [J].
Bindewald, A ;
Bird, AC ;
Dandekar, SS ;
Dolar-Szczasny, J ;
Dreyhaupt, J ;
Fitzke, FW ;
Einbock, W ;
Holz, FG ;
Jorzik, JJ ;
Keilhauer, C ;
Lois, N ;
Mlynski, J ;
Pauleikhoff, D ;
Staurenghi, G ;
Wolf, S .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (09) :3309-3314
[5]   Iron-Chelating Therapy for Transfusional Iron Overload [J].
Brittenham, Gary M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (02) :146-156
[6]   OCULAR AND AUDITORY TOXICITY IN HEMODIALYZED PATIENTS RECEIVING DESFERRIOXAMINE [J].
CASES, A ;
KELLY, J ;
SABATER, F ;
TORRAS, A ;
GRINO, MC ;
LOPEZPEDRET, J ;
REVERT, L .
NEPHRON, 1990, 56 (01) :19-23
[7]   Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients [J].
Chen, SH ;
Liang, DC ;
Lin, HC ;
Cheng, SY ;
Chen, LJ ;
Liu, HC .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2005, 27 (12) :651-653
[8]   VISION AND HEARING DURING DEFEROXAMINE THERAPY [J].
COHEN, A ;
MARTIN, M ;
MIZANIN, J ;
KONKLE, DF ;
SCHWARTZ, E .
JOURNAL OF PEDIATRICS, 1990, 117 (02) :326-330
[9]  
DAVIES SC, 1983, LANCET, V2, P181
[10]  
DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718